Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 18:47:31 GMT 2023
by
admin
on
Sat Dec 16 18:47:31 GMT 2023
|
Protein Type | BISPECIFIC ANTIBODY |
Protein Sub Type | IGG1 |
Sequence Type | COMPLETE |
Record UNII |
U4T9GD9GR9
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C169052
Created by
admin on Sat Dec 16 18:47:31 GMT 2023 , Edited by admin on Sat Dec 16 18:47:31 GMT 2023
|
PRIMARY | |||
|
U4T9GD9GR9
Created by
admin on Sat Dec 16 18:47:31 GMT 2023 , Edited by admin on Sat Dec 16 18:47:31 GMT 2023
|
PRIMARY | |||
|
11793
Created by
admin on Sat Dec 16 18:47:31 GMT 2023 , Edited by admin on Sat Dec 16 18:47:31 GMT 2023
|
PRIMARY | |||
|
2417199-08-5
Created by
admin on Sat Dec 16 18:47:31 GMT 2023 , Edited by admin on Sat Dec 16 18:47:31 GMT 2023
|
PRIMARY | |||
|
KL-61
Created by
admin on Sat Dec 16 18:47:31 GMT 2023 , Edited by admin on Sat Dec 16 18:47:31 GMT 2023
|
PRIMARY |
From | To |
---|---|
1_617 | 2_353 |
4_139 | 4_199 |
4_23 | 4_93 |
3_215 | 3_271 |
1_492 | 2_233 |
1_489 | 2_230 |
2_371 | 2_429 |
2_265 | 2_325 |
2_224 | 4_219 |
2_148 | 2_204 |
2_22 | 2_96 |
1_483 | 3_291 |
1_630 | 1_688 |
1_524 | 1_584 |
1_403 | 1_463 |
Glycosylation Type | MAMMALIAN |
Glycosylation Link Type | Site |
---|---|
N | 1_560 |
N | 2_301 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
The underlying mode of action of this
molecule is to enhance the effector function of tumor-infiltrating T-cells or NK-cells upon
activation by a tumor-targeted T-cell bispecific (TCB) antibody or antibody-dependent cellular cytotoxicity (ADCC), respectively, by crosslinking 4-1BB-positive activated effector cells with CD19+ tumor targets.
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Molecular Formula | CHEMICAL |
|
||||
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|